AITKEN_PHARMACY_LIMITED - Accounts

Company Registration No. SC219159 (Scotland)
AITKEN PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2018
PAGES FOR FILING WITH REGISTRAR
AITKEN PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mr G Coventry
Mrs P Coventry
Secretary
Mrs P Coventry
Company number
SC219159
Registered office
67 High Street
Dunbar
East Lothian
EH42 1EW
Accountants
Geoghegans Accountancy Limited
Chartered Accountants
6 St Colme Street
Edinburgh
EH3 6AD
AITKEN PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 8
AITKEN PHARMACY LIMITED
BALANCE SHEET
AS AT
31 MAY 2018
31 May 2018
- 1 -
2018
2017
Notes
£
£
£
£
Fixed assets
Tangible assets
4
5,774
7,699
Investments
5
23,457
227,433
29,231
235,132
Current assets
Stocks
40,889
40,166
Debtors
6
346,766
266,561
Cash at bank and in hand
504,771
246,392
892,426
553,119
Creditors: amounts falling due within one year
7
(276,133)
(202,527)
Net current assets
616,293
350,592
Total assets less current liabilities
645,524
585,724
Provisions for liabilities
(982)
(1,309)
Net assets
644,542
584,415
Capital and reserves
Called up share capital
8
100
100
Revaluation reserve
9
3,457
27,433
Profit and loss reserves
640,985
556,882
Total equity
644,542
584,415

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 May 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

AITKEN PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MAY 2018
31 May 2018
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 20 September 2018 and are signed on its behalf by:
Mr G Coventry
Director
Company Registration No. SC219159
AITKEN PHARMACY LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2018
- 3 -
Share capital
Revaluation reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 June 2016
100
18,843
655,222
674,165
Year ended 31 May 2017:
Profit and total comprehensive income for the year
-
-
30,250
30,250
Dividends
-
-
(120,000)
(120,000)
Transfers
-
8,590
(8,590)
-
Balance at 31 May 2017
100
27,433
556,882
584,415
Year ended 31 May 2018:
Profit and total comprehensive income for the year
-
-
180,127
180,127
Dividends
-
-
(120,000)
(120,000)
Transfers
-
(23,976)
23,976
-
Balance at 31 May 2018
100
3,457
640,985
644,542
AITKEN PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2018
- 4 -
1
Accounting policies
Company information

Aitken Pharmacy Limited is a private company limited by shares incorporated in Scotland. The registered office is 67 High Street, Dunbar, East Lothian, EH42 1EW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of investments at fair value. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents amounts receivable for goods and services net of VAT.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Fixed asset investments are stated at valuation.

1.5
Impairment of fixed assets

The carrying value of tangible fixed assets are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

1.7
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

AITKEN PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2018
1
Accounting policies
(Continued)
- 5 -
1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors

Debtors with no stated interest or receivable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Creditors

Creditors with no stated interest rate and payable within one year are recorded at transaction price.

 

All interest bearing loans and borrowings which are basic financial instruments are initially recorded at the present value of cash payable. After initial recognition they are measured at amortised cost.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

AITKEN PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2018
1
Accounting policies
(Continued)
- 6 -
1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 11 (2017 - 11).

3
Intangible fixed assets
Goodwill
£
Cost
At 1 June 2017 and 31 May 2018
250,000
Amortisation and impairment
At 1 June 2017 and 31 May 2018
250,000
Carrying amount
At 31 May 2018
-
At 31 May 2017
-
AITKEN PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2018
- 7 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 June 2017 and 31 May 2018
76,716
Depreciation and impairment
At 1 June 2017
69,017
Depreciation charged in the year
1,925
At 31 May 2018
70,942
Carrying amount
At 31 May 2018
5,774
At 31 May 2017
7,699
5
Fixed asset investments
2018
2017
£
£
Investments
23,457
227,433
Fixed asset investments revalued

The investments are included at market value, as valued by The Prudential Assurance Company on 17 May 2018. The historical cost of the investments held at 31 May 2018 is £20,000.

6
Debtors
2018
2017
Amounts falling due within one year:
£
£
Trade debtors
199,310
146,883
Other debtors
147,456
119,678
346,766
266,561
7
Creditors: amounts falling due within one year
2018
2017
£
£
Trade creditors
223,981
185,085
Corporation tax, other taxation and social security
49,694
14,802
Other creditors
2,458
2,640
276,133
202,527
AITKEN PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2018
- 8 -
8
Called up share capital
2018
2017
£
£
Ordinary share capital
Issued and fully paid
100 Ordinary shares of £1 each
100
100
100
100
9
Revaluation reserve
2018
2017
£
£
At beginning of year
27,433
18,843
Transfer (to)/from retained earnings
(23,976)
8,590
At end of year
3,457
27,433
10
Directors' transactions
Description
% Rate
Opening balance
Amounts advanced
Interest charged
Closing balance
£
£
£
£
Advanced by company
3.00
79,113
16,172
2,859
98,144
79,113
16,172
2,859
98,144

The directors are of the opinion that all other related party transactions are conducted under normal market conditions and on an arm's length basis and therefore do not need to be disclosed under FRS 102 section 1A appendix C.

2018-05-312017-06-01falseCCH SoftwareCCH Accounts Production 2018.220No description of principal activity20 September 2018Mr G CoventryMrs P CoventryMrs P CoventrySC2191592017-06-012018-05-31SC219159bus:Director12017-06-012018-05-31SC219159bus:CompanySecretaryDirector12017-06-012018-05-31SC219159bus:Director22017-06-012018-05-31SC219159bus:CompanySecretary12017-06-012018-05-31SC219159bus:RegisteredOffice2017-06-012018-05-31SC2191592018-05-31SC2191592017-05-31SC219159core:OtherPropertyPlantEquipment2018-05-31SC219159core:OtherPropertyPlantEquipment2017-05-31SC219159core:CurrentFinancialInstruments2018-05-31SC219159core:CurrentFinancialInstruments2017-05-31SC219159core:ShareCapital2018-05-31SC219159core:ShareCapital2017-05-31SC219159core:RevaluationReserve2018-05-31SC219159core:RevaluationReserve2017-05-31SC219159core:RetainedEarningsAccumulatedLosses2018-05-31SC219159core:RetainedEarningsAccumulatedLosses2017-05-31SC219159core:ShareCapitalOrdinaryShares2018-05-31SC219159core:ShareCapitalOrdinaryShares2017-05-31SC219159core:RevaluationReserve2017-05-31SC2191592016-06-012017-05-31SC219159core:RetainedEarningsAccumulatedLosses2017-06-012018-05-31SC219159core:RetainedEarningsAccumulatedLosses2016-06-012017-05-31SC219159core:FurnitureFittings2017-06-012018-05-31SC219159core:NetGoodwill2017-05-31SC219159core:OtherPropertyPlantEquipment2017-05-31SC219159core:OtherPropertyPlantEquipment2017-06-012018-05-31SC219159bus:OrdinaryShareClass12017-06-012018-05-31SC219159bus:OrdinaryShareClass12018-05-31SC219159bus:PrivateLimitedCompanyLtd2017-06-012018-05-31SC219159bus:FRS1022017-06-012018-05-31SC219159bus:AuditExemptWithAccountantsReport2017-06-012018-05-31SC219159bus:SmallCompaniesRegimeForAccounts2017-06-012018-05-31SC219159bus:FullAccounts2017-06-012018-05-31xbrli:purexbrli:sharesiso4217:GBP